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Summary: it was made a comparative study of Ukrainian and Polish pharmaceutical markets of medications used for 
treatment of chronic obstructive pulmonary disease. Also it was analyzed the structure of the assortment of the researched 
group due to the manufacturing countries, dosage forms and composition of active pharmaceutical ingredients and their 
origin. The results of market research can determine the main ways of domestic assortment improvement of medications 
studied at the pharmaceutical and therapeutic group.
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Introduction. Nowadays, chronic obstructive pulmo-
nary disease (COPD) is one of the biggest health prob-
lem. It is a major cause of morbidity and mortality in the 
world due to the medical, social and economic terms. 
Thus, according to the latest data of the World Health 
Organization, currently about 210 million people are suf-
fering from COPD and more than 2.75 million people die 
of COPD each year [1]. Late diagnosis and inappropri-
ate treatment lead to incapacitation and early disability. 
After 10 years, every fourth ill patient with COPD be-
comes disabled [2].
In accordance with the mentioned above information, 
comparative marketing analysis of medication assort-
ment for the treatment of COPD are currently important 
at the domestic pharmaceutical market and at the mar-
ket of Poland as one of the most developed markets of 
the European Union to determine the feasibility of de-
veloping new medications and the possibility to take the 
particular market  eld.
Research methods.
During the study it was used general rules for second-
ary collecting market information, methods of mathe-
matical statistics. The information technologies are used 
for processing the results of the research. The analysis 
of the range of medication was done according to the 
classi cation of Anatomical Therapeutic Chemical (ATC) 
system using secondary information of electronic data-
base of the State Registry of Medicines, Compendium, 
Pharmindex and data of information and analytical sys-
tem «Baza leków DrWidget» [3–6].
Results and discussion. The objects of the study 
were medications of R03 group «Medications used for 
the obstructive respiratory diseases» (according to the 
ATC classi cation): adrenergic medications for inhala-
tion use (group R03A), inhaled asthma agents (group 
R03B), adrenergic medications for regular use (group 
R03C), other medications for regular use of the obstruc-
tive respiratory diseases (group R03D) [6]. Market re-
search of medications for the treatment of COPD was 
performed on various parameters, including the manu-
facturing countries, dosage form and content of active 
pharmaceutical ingredients and their origin.
Studying the medication assortment and patterns of 
R03 «Medications used for the obstructive respiratory 
diseases» at Ukrainian market showed that for the date 
of May 2015 the State Registry of Medicines included 
18 trade names (21.43 %) of domestic production and 
66 names (78.57 %) of foreign production, indicating a 
signi cant dominance of import at the research  eld of 
the domestic market.
These market analyses show that among foreign 
manufacturers of medication for COPD treatment at 
Ukrainian pharmaceutical market, 4 countries take the 
leading position: the Great Britain, Spain, Poland and 
India, the share of each country is 12.12 % (8 medica-
tions) of researched assortment, Ireland and Sweden 
– 9.1 % (6 medications) and 7.56 % (5 medications) 
respectively. Overall offers come from pharmaceutical 
companies of 17 different countries to Ukrainian phar-
maceutical market.
The domestic part of studied assortment of pharma-
cotherapeutic group at the pharmaceutical market in 
Ukraine is provided by 7 Ukrainian industrial enterprises, 
especially: Yuriya Farm, LLC; Mikrofarm, LLC; FF Dar-
nitsa, CJSC; Borshchahivskyy CPP, PJSC; Niko, LLC; 
FF Health, LLC; Interhim, LLC.
As a result of market research in Poland, we found 
that the product assortment of R03 «Medications used 
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for the obstructive diseases of respiratory diseases" is 
mostly formed by foreign manufacturers. In particular, 
the number of foreign medications, of studied pharma-
cotherapeutic group, is generally higher in 4 times than 
the number of domestic medication production, indicat-
ing a signi cant dominance of import (80%) at the stud-
ied  eld.
Based on the analysis of medications registered in 
Poland for COPD treatment due to the manufacturing 
countries, it was found that 21.74 % (40 names) – medi-
cations produced in the Great Britain (leading manufac-
turers are GlaxoSmithKline, AstraZeneca), 18.47 % (34 
medications) – Germany (Boehringer Ingelheim, San-
doz), 11.96 % (22 medications) – Switzerland (Novartis), 
and 7.07 % (13 medications) of investigated assortment 
are produced in Israel (Teva Pharmaceutical Industries). 
Generally, the results of the research on importing coun-
tries for COPD treatment show that the delivery of these 
medications to the pharmaceutical market in Poland are 
performed by 18 countries of the world but their share 
of each totally is not higher than 5 % of general assort-
ment.
The domestic pharmaceutical company Orion Phar-
ma (9 names) is a leader by the number of assortment 
items produced for Polish market, the second place has 
company Polpharma (7 names), the third place gets the 
company Polfarmex SA, which produces 6 medications 
for COPD treatment.
For more detailed study of investigation market  elds, 
we have analyzed medications due to the form of re-
lease. In particular, analysis of the medication assort-
ment for COPD treatment registered in Ukraine, due 
to the dosage forms has showed that the main share 
(23.81 %) is presented as aerosols, 19.05 % of medica-
tions are powders for inhalation, 18.34 % of researched 
group are coated tablets (Fig. 1).
Other medications, such as prolonged and chewing 
tablets, suspensions and solutions for inhalation, oral 
drops, syrups, solutions and powder injection, capsules, 
enteric and inhalation under pressure amount together 
approximately 48.80 % of the assortment in this group at 
the market Ukraine.
The comparison of suggested assortment of R03 
group, represented at the pharmaceutical market in Po-
land (Fig. 2) on medication forms, indicates that the larg-
est share in this aspect are chewing tablets – 29.57 % 
(68 medications), powders for inhalation – 22.60 % (52 
medications), coated tablets – 16.96 % (39 medications) 
and aerosols – 13,04 % (30 medications).
It should be mentioned that at the market of Ukraine 
in the assortment of the researched group there are 
no such dosage forms as modi ed capsules (Euphyl-
lin Long, Takeda Pharma, Denmark), granules for oral 
solution preparation (Montelukast-1A Pharma, 1A Phar-
ma, Germany) solution infusion (Theophyllinum, Baxter, 
USA) and rectal suppositories (Theovent 350, GlaxoS-
mithKline, UK).
The next phase of the study involved the research 
of proportion of medications for COPD treatment due 
to the origin of active pharmaceutical ingredients. The 
researched assortment of medications at Ukrainian mar-
ket is represented only by synthetic medications. Medi-
cations based on montelukast (12 medications), the 
second place – theophylline (9 medications) and third 
Fig. 1. Assortment distribution of medication for COPD treatment due to the dosage form at the market of Ukraine
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Fig. 2. Assortment distribution of medication for COPD treatment due to the dosage form at the market of Poland
– budesonide and  uticasone (8 medications) are the 
leaders of the researched group. It should be mentioned 
that monocomponent medications dominate among the 
studied medications. The share of combination medica-
tions is small (17.85 %).
The medication assortment for COPD treatment at 
Polish market is represented similarly as in Ukraine, only 
synthetic medications, while the main group of medica-
tions is based on montelukast (114 medications), the 
second place and the third place – salbutamol (17 medi-
cations) and budesonide (13 medications), respectively. 
The analysis of studied medications shows that amount 
of monocomponent medications (88.26 %) is bigger.
Comparative studies have shown the absence at 
the market of Ukraine the following active pharma-
ceutical ingredients and their combinations: combina-
tion – vilanterol and ipratropium bromide (trade name 
Anoro, Laventair, GlaxoSmithKline, UK); combination 
– indakaterol of glycopyrronium bromide (trade name 
Ultibro Breezhaler, Xoterna Breezhaler, Novartis, Swit-
zerland); glycopyrronium bromide (trade name Enurev 
Breezhaler, Seebri Breezhaler, Tovanor Breezhaler No-
vartis, Switzerland); umeclidinium bromide (trade name 
Incruse, GlaxoSmithKline, UK); za rlukast (brand name 
Accolate, AstraZeneca, UK).
A comparative studies of medication assortment for 
COPD treatment at the markets of Ukraine and Poland 
can determine the main ways for improvement of do-
mestic assortment of medications at researched phar-
macotherapeutic group.
Conclusions: 
1. It was studied the medication assortment for 
COPD treatment listed on the pharmaceutical markets 
in Ukraine and Poland. As a result of studies, it was 
found that the products in both countries are generally 
represented by foreign manufacturers, particularly in 
Ukraine, their market share is 78.57 %, while in Poland 
– 80 %.
2. The market analysis data indicates that among for-
eign manufacturers of medication for COPD treatment 
at Ukrainian pharmaceutical market leading positions 
are occupied by 4 countries: the Great Britain, Spain, 
Poland and India; at the Polish market, the following 
countries are the leaders of medication delivery: the 
Great Britain, Germany, Switzerland and Israel.
3. The comparison of assortment represented at the 
pharmaceutical market of Ukraine and Poland on the 
dosage form indicates that the largest share has aero-
sols (23.81 %) at Ukrainian market and chewable tablets 
(29.57 %) at Polish.
4. The medication assortment for COPD treatment is 
represented only with synthetic drugs at both pharma-
ceutical markets, while the main group in Ukraine is a 
group of medications based on montelukast, theophyl-
line, budesonide,  uticasone and in Poland – montelu-
kast, salbutamol, budesonide.
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ПОРІВНЯЛЬНИЙ АНАЛІЗ АСОРТИМЕНТУ ЛІКАРСЬКИХ ЗАСОБІВ ДЛЯ ЛІКУВАННЯ ХРОНІЧНОГО 
ОБСТРУКТИВНОГО ЗАХВОРЮВАННЯ ЛЕГЕНЬ, ПРЕДСТАВЛЕНИХ НА УКРАЇНСЬКОМУ ТА 
ПОЛЬСЬКОМУ ФАРМАЦЕВТИЧНИХ РИНКАХ
О. І. Онишків, Т. А. Грошовий, І. П. Лех 
Тернопільський державний медичний університет імені І. Я. Горбачевського
Резюме: проведено порівняльне дослідження українського та польського фармацевтичних ринків лікарських 
засобів, які застосовують для лікування хронічного обструктивного захворювання легень. Проаналізовано структуру 
асортименту досліджуваної групи за країнами-виробниками, лікарською формою, а також вмістом активних 
фармацевтичних інгредієнтів та їх походженням. Результати проведених маркетингових досліджень дозволяють 
визначити основні напрямки удосконалення вітчизняного асортименту препаратів досліджуваної фармако-
терапевтичної групи.
Ключові слова: лікарські засоби для лікування хронічного обструктивного захворювання легень, фармацевтичний 
ринок України та Польщі.
СРАВНИТЕЛЬНЫЙ АНАЛИЗ АССОРТИМЕНТА ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ 
ХРОНИЧЕСКОГО ОБСТРУКТИВНОГО ЗАБОЛЕВАНИЯ ЛЕГКИХ, ПРЕДСТАВЛЕННЫХ НА 
УКРАИНСКОМ И ПОЛЬСКОМ ФАРМАЦЕВТИЧЕСКИХ РЫНКАХ
О. И. Онышкив, Т. А. Грошовый, И. П. Лех
Тернопольский государственный медицинский университет имени И. Я. Горбачевского
Резюме: проведено сравнительное исследование украинского и польского фармацевтических рынков препаратов, 
применяемых для лечения хронического обструктивного заболевания легких. Проанализирована структура 
ассортимента исследуемой группы по странам-производителям, лекарственной форме, а также содержанием 
активных фармацевтических ингредиентов и их происхождению. Результаты проведенных маркетинговых 
исследований позволяют определить основные направления совершенствования отечественного ассортимента 
препаратов исследуемой фармако-терапевтической группы.
Ключевые слова: лекарственные средства для лечения хронического обструктивного заболевания легких, 
фармацевтический рынок Украины и Польши.
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